title: Differences in circulating insulin levels following glargine administration.
abstract: OBJECTIVE
  To evaluate two-site non competitive insulin immunoassays [BI-INSULIN assay (IRMA) and an electro-chemiluminescent immunoassay (ECLIA)] in routine practice.
  
  
  METHODS
  We studied 145 consecutive patients attending our Endocrine Department for general endocrine explorations and metabolic status investigations.
  
  
  RESULTS
  The ECLIA yielded higher results than IRMA in all but six patients treated by glargine.
  
  
  CONCLUSIONS
  Insulin levels measured by Elecsys in patients treated by glargine are directly related to glargine biotransformation into detectable metabolite (M1).
authors.affiliation: Unit of Transfert in Molecular Oncology and Hormonology, Saint-Louis University Hospital, Assistance-Publique Hôpitaux de Paris, France.
authors.forename: Fidaa
authors.initials: F
authors.lastname: Ibrahim
authors.forename: Georges
authors.initials: G
authors.lastname: Bagnard
authors.forename: Philippe
authors.initials: P
authors.lastname: Boudou
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000378:metabolism; D015592:Immunoradiometric Assay / Q000379:methods*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008163:Luminescent Measurements / Q000379:methods*; D008297:Male; D008875:Middle Aged
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine